• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

    307.83 +0.08 (+0.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Praxis Precision Medicines, Inc. - Common Stock

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    News headline image
    Where Praxis Precision Medicine Stands With Analysts ↗
     
    Via Benzinga
    News headline image
    Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023 ↗
     
    Via Benzinga
    News headline image
    What 5 Analyst Ratings Have To Say About Praxis Precision Medicine ↗
     
    Via Benzinga
    News headline image
    Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Recap: Praxis Precision Medicine Q1 Earnings ↗
     
    Via Benzinga
    News headline image
    Top 5 Health Care Stocks That May Fall Off A Cliff ↗
    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
    Via Benzinga
    News headline image
    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗
    Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
    Via Benzinga
    News headline image
    Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Proposed Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023 ↗
     
    Via Benzinga
    News headline image
    Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy ↗
    Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and  
    Via Benzinga
    News headline image
    Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
    Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023 
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗
    The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023 ↗
     
    Via Benzinga
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.